Cargando…

Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors

OBJECTIVE: The purpose of this study was to evaluate the prognostic impact of body composition parameters based on computed tomography (CT) in patients with non-small cell lung cancer (NSCLC) who received ICI treatment. METHODS: This retrospective study analyzed the data from advanced NSCLC patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Ji Eun, Jo, Jaemin, Youk, Jeonghwan, Kim, Miso, Yoon, Soon Ho, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong-Wan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600077/ https://www.ncbi.nlm.nih.gov/pubmed/37880430 http://dx.doi.org/10.1186/s13244-023-01532-4

Ejemplares similares

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019)

Artificial intelligence‐powered spatial analysis of tumor‐infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single‐center, retrospective, longitudinal cohort study
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
por: Park, Changhee, et al.
Publicado: (2019)

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment
por: Park, Changhee, et al.
Publicado: (2021)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
por: Choi, Ji Young, et al.
Publicado: (2019)

HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor
por: Chang, Hyeyeon, et al.
Publicado: (2020)

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin
por: Kim, Ahwon, et al.
Publicado: (2019)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
por: Kim, Miso, et al.
Publicado: (2023)

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
por: Kim, Ryul, et al.
Publicado: (2019)

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
por: Kim, Ryul, et al.
Publicado: (2016)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma
por: Kwon, Dohee, et al.
Publicado: (2016)

Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Jung, Eun Hee, et al.
Publicado: (2021)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines
por: Lee, Jeongjae, et al.
Publicado: (2022)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
por: Ock, Chan-Young, et al.
Publicado: (2019)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration
por: Kim, Sehui, et al.
Publicado: (2022)

Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis
por: Park, Ha-Ram, et al.
Publicado: (2022)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
por: Seo, Ja Young, et al.
Publicado: (2021)

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
por: Choi, Yeonjoo, et al.
Publicado: (2019)

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2017)

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
por: Shin, Junghoon, et al.
Publicado: (2017)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kim, Hyun Jee, et al.
Publicado: (2018)

Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
por: Heo, Ja Yoon, et al.
Publicado: (2021)

The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study
por: Lee, Jaewon, et al.
Publicado: (2018)

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations
por: Park, Sehhoon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ltkpiponrt950638sbb65sbj9d